Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Retained Earnings: 2020-2024

Historic Retained Earnings for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to -$448.4 million.

  • Caribou Biosciences' Retained Earnings fell 38.05% to -$570.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$570.0 million, marking a year-over-year decrease of 38.05%. This contributed to the annual value of -$448.4 million for FY2024, which is 49.82% down from last year.
  • Latest data reveals that Caribou Biosciences reported Retained Earnings of -$448.4 million as of FY2024, which was down 49.82% from -$299.3 million recorded in FY2023.
  • Caribou Biosciences' Retained Earnings' 5-year high stood at -$30.9 million during FY2020, with a 5-year trough of -$448.4 million in FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$299.3 million (2023), whereas its average is -$315.0 million.
  • Data for Caribou Biosciences' Retained Earnings shows a maximum YoY plummeted of 216.78% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Caribou Biosciences' Retained Earnings stood at -$30.9 million in 2020, then slumped by 216.78% to -$97.8 million in 2021, then crashed by 101.66% to -$197.2 million in 2022, then tumbled by 51.76% to -$299.3 million in 2023, then crashed by 49.82% to -$448.4 million in 2024.